8-K
Adial Pharmaceuticals, Inc. (ADIL)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the SecuritiesExchange Act of 1934
Date of Report (date of earliest event reported): June 11, 2020
Adial Pharmaceuticals, Inc.
(Exact name of registrant as specified incharter)
Delaware
(State or other jurisdiction of incorporation)
| 001-38323 | 82-3074668 |
|---|---|
| (Commission File Number) | (IRS Employer Identification No.) |
1001 Research Park Blvd., Suite 100
Charlottesville, Virginia 22911
(Address of principal executive offices andzip code)
(434) 422-9800
(Registrant’s telephone number includingarea code)
(Former Name and Former Address)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbols | Name of each exchange on which registered |
|---|---|---|
| Common Stock | ADIL | NASDAQ |
| Warrants | ADILW | NASDAQ |
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. OtherEvents.
On June 11, 2020, Adial Pharmaceuticals, Inc. (“Adial” or the “Company”) issued a press release announcing that it had received all necessary approvals to commence its landmark ONWARD™ pivotal Phase 3 clinical trial in Poland to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes.
A copy of the press release is attached as Exhibit 99.1 to this Report on Form 8-K.
Item 9.01. FinancialStatements and Exhibits.
(d) Exhibits
The following exhibit is filed with this Current Report on Form 8-K:
| Exhibit No | Description |
|---|---|
| 99.1 | Press Release issued by Adial Pharmaceuticals, Inc. dated June 11, 2020. |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: June 11, 2020 | ADIAL PHARMACEUTICALS, INC. | |
|---|---|---|
| By: | /s/ William B. Stilley, III | |
| Name: | William B. Stilley | |
| Title: | President and Chief Executive Officer |
2
Exhibit 99.1
Adial Pharmaceuticals Announces Approvalto Commence Landmark ONWARD™ Pivotal Phase 3 Trial in Poland
Achievement of Poland Approval an ImportantMilestone in Advancement of Trial
Trial Progress Accelerates as Host CountriesReopen Following COVID-19 Lockdowns
Charlottesville, VA – June 11, 2020– Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received all necessary approvals to commence its landmark ONWARD™ pivotal Phase 3 clinical trial in Poland to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder in persons with certain target genotypes related to the serotonin transporter and receptor genes. This includes the receipt of approvals from both the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products and the relevant regional Polish Ethics Committees overseeing the trial.
“Poland is one of the largest countries in Europe and we believe it is critical to the successful rapid recruitment of patients into our landmark ONWARD™ trial,” stated Schuyler Vinzant, Vice President of Development of Adial Pharmaceuticals. “Regulatory review in Poland was put on hold due to the COVID-19 pandemic. When regulatory reviews recently restarted, the speed of approval to commence the ONWARD™ trial was unexpectedly fast. We are excited by the prospect of opening sites in Poland in the next few weeks.”
“We are grateful the Polish authorities determined the ONWARD™ pivotal Phase 3 trial justified rapid approval,” commented William Stilley, Chief Executive Officer of Adial Pharmaceuticals. “We believe this further demonstrates that regulatory authorities recognize we are targeting an unmet medical need with a drug with the potential to be safe and effective. Today, there is no adequate treatment for Alcohol Use Disorder, and there are strong indications that the problem has only gotten worse during COVID-19 lockdowns. It is imperative that the world moves to bring additional treatments to those suffering with addiction. We are highly confident in our genetically-targeted approach with AD04 and our trial is designed to achieve statistical significance against placebo using endpoints correlated to improved quality of life and reduction in harm (e.g., less death, cancer, accidents, missed work, etc.). The approval to commence the trial in Poland is a landmark achievement in the advancement of our trial.”
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. www.adialpharma.com
About BioLab Sciences, Inc.
BioLab Sciences is a regenerative medicine company focused on creating new ways to regenerate the body for optimal performance. Headquartered in Scottsdale, Arizona, BioLab Sciences is expanding the human body’s ability to regenerate by developing and manufacturing human cell and tissue therapies as an alternative to invasive, painful and expensive treatment protocols. Through research and innovation, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. Learn more at www.biolabsciences.net.
Forward Looking Statements
This communication contains certain “forward-lookingstatements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derivedutilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may causeactual results, performance or achievements to be materially different from any future results, performance or achievements expressedor implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,”“expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans”and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may”and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statementsinclude the foregoing. The forward-looking statements include statements regarding Poland being critical to the successfulrapid recruitment of patients into our landmark ONWARD™ trial, the prospect of opening sites in Poland in the next few weeks,the regulatory authorities recognizing we are targeting an unmet medical need with a drug with the potential to be safe and effectiveand the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-lookingstatements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others,our ability to open sites in Poland in the next one to two weeks, our ability to expand the use of AD04 for use in patients withOpioid Use Disorder, gambling and obesity, the ability of AD04 therapy to perform as designed, to demonstrate safetyand efficacy, as well as results that are consistent with prior results, our ability to enroll patients and complete the clinicaltrials on time and achieve desired results and benefits, our ability to obtain regulatory approvals for commercialization of productcandidates or to comply with ongoing regulatory requirements, regulatory limitations relating to our ability to promote or commercializeour product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development,marketing or sale of products, our ability to maintain our license agreements, the continued maintenance and growth of our patentestate, our ability to establish and maintain collaborations, our ability to obtain or maintain the capital or grants necessaryto fund its research and development activities, and our ability to retain our key employees or maintain our Nasdaq listing. Theserisks should not be construed as exhaustive and should be read together with the other cautionary statement included in our AnnualReport on Form 10-K for the year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q and current reports on Form8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it wasinitially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of newinformation, future events, changed circumstances or otherwise, unless required by law.
Contact:
Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: [email protected]